吲哚胺2,3-双加氧酶1在胃癌中的研究进展

Research progress of indoleamine 2,3-dioxygenase 1 in gastric cancer

胃癌(Gastric Cancer,GC)是全球第五大最常见的恶性肿瘤,也是第四大癌症死亡相关原因。胃癌异质性明显,肿瘤微环境复杂,免疫检查点抑制剂虽然在晚期胃癌中展现出一定抗肿瘤疗效,但获益人群仍在少数。吲哚胺2,3-双加氧酶1(Indoleamine 2,3-Dioxygenase 1,IDO1)是色氨酸沿犬尿氨酸途径代谢中的关键酶,对肿瘤免疫逃逸起到了关键作用。目前已有多项研究表明IDO1在胃癌发生发展及幽门螺杆菌感染和EB病毒感染中发挥重要作用,所以靶向IDO1有望成为胃癌免疫治疗的新策略。本文就IDO1作用机制、IDO1在胃癌及相关疾病中的研究进展及IDO1抑制剂在胃癌中的应用前景进行综述。

Gastric cancer is the fifth most common malignant tumor and fourth leading cause of cancer related deaths worldwide.Gastric cancer has obvious heterogeneity and complex tumor microenvironment.Although immune checkpoint inhibitors have shown certain anti-tumor efficacy in advanced gastric cancer,the beneficiaries are still a few.Indoleamine 2,3-dioxygenase 1(IDO1)is a key metabolic enzyme which catalyzes the degradation of tryptophan along the kynurenine pathway and plays an important role in tumor immune escape.At present,many studies have shown that IDO1 plays an important role in the development of gastric cancer,Helicobacter pylori infection and EB virus infection.Therefore,targeting IDO1 is expected to become a new strategy for immunotherapy of gastric cancer.This paper reviews the mechanism of IDO1,the research progress of IDO1 in gastric cancer and related diseases and the application prospect of IDO1 inhibitors in gastric cancer.